Intervention, randomization, and outcomes
PMR
Patients with newly diagnosed PMR were randomized (1/1) to the tofacitinib (5 mg BID) group and the glucocorticoids (Pred 15 mg/day, gradually tapered) group using an envelope by a statistician who was not involved in the trial conduct. Rheumatologists enrolled participants, while statistician assigned participants to interventions. Statistician created 94 random numbers (from 0 to 100) using an online tool (The primary endpoint was the proportion of patients with PMR-AS < 10 at weeks 12 and 24. Secondary endpoints: PMR-AS score, CRP, and ESR at weeks 12 and 24. Patient information on demographic data, clinical features, serological profiles, and medications was obtained from medical records.